Restart Life SciencesNMLSF Gross Margin % is 45.92% as of Mar. 2026, which is 96% above its 10-year median of 23.38. The stock has 3 warning signs investors should review. Among 737 Biotechnology companies, Restart Life Sciences ranks worse than 64.04% on this metric.
NMLSF's Gross Margin % is ranked worse than 64.04% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs NMLSF: 45.93
Restart Life Sciences had a gross margin of 45.92% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Restart Life Sciences was 0.00% per year.
Restart Life Sciences (OTCPK:NMLSF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Restart Life Sciences had a gross margin of 45.92% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Restart Life Sciences Gross Margin % Related Terms
Restart Life Sciences Gross Margin % Historical Data
* Premium members only.
The historical data trend for Restart Life Sciences's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NMLSF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Restart Life Sciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Restart Life Sciences Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Restart Life Sciences's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Restart Life Sciences (NMLSF) has a Gross Margin % of 45.92% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Restart Life Sciences and its competitors. This is 96% above median its historical median of 23.38. Over the past decade, Restart Life Sciences' Gross Margin % has ranged from 18.18 to 45.93. According to the industry distribution chart, Restart Life Sciences ranks #472 out of 737 companies in the Biotechnology industry, placing it in the top 64%.
Is Restart Life Sciences' Gross Margin % too high?
Restart Life Sciences' current Gross Margin % of 45.92% is 96% above median its 10-year median of 23.38. Over the past 10 years, this metric has ranged from a low of 18.18 to a high of 45.93. The Biotechnology industry median Gross Margin % is 60.92. Restart Life Sciences' value of 45.92% is 24.6% below this industry median. Based on the distribution chart, Restart Life Sciences ranks #472 out of 737 companies in the Biotechnology industry, which is below the industry midpoint.
How does Restart Life Sciences' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Restart Life Sciences ranks #472 out of 737 companies for Gross Margin %. This places Restart Life Sciences in the lower half of its industry. The industry median Gross Margin % is 60.92. Restart Life Sciences' value of 45.92% is 24.6% below this benchmark. Historically, Restart Life Sciences' own Gross Margin % has ranged from 18.18 to 45.93 over the past decade. While the company's 10-year median is 23.38 vs. the industry median of 60.92, Restart Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Restart Life Sciences's current Gross Margin % of 45.92% is 24.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Restart Life Sciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Restart Life Sciences's current Gross Margin % is 45.92%, which is 96% above median its own 10-year median of 23.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Restart Life Sciences stock overvalued right now?
Restart Life Sciences (NMLSF) has a current Gross Margin % of 45.92%. The current Gross Margin % is 45.92%, which is 96% above median its 10-year median of 23.38 and 24.6% below the Biotechnology industry median of 60.92. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Restart Life Sciences (NMLSF), the current Gross Margin % is 45.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Restart Life Sciences Corp is a Canadian-based life sciences company dedicated to addressing health challenges with wellness solutions. Its brands include HolyCrap, BrainQ, Brain Balls.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMLSF has been successfully added to your 